The transmission and use of personal data is a complex matter that cannot be adequately processed on this website. Duke researchers who wish to transfer or use human data should contact ORC to initiate a debate about the transmission or use of proposed data. New inventions or discoveries, developed exclusively through trials, are considered royalties and are made available to all participating parties as such. All participating parties agree that the payment made is fairly in the market for such participation and that no payment has been made for the outcome of the process. None of the parties involved were unfairly paid or paid for certain results. The transmission and use of data is generally only intended as a summary and not as a complete guide to the transmission or use of data, in general, by various important considerations, including those relating to the duke IRB rules, the Health Insurance Portability and Accountability Act of 1996 as amended (“HIPAA”), ethical considerations as to whether or not the transmission and/or use of the data is subject to contractual restrictions, and intellectual property issues. A researcher who wishes to transfer or use data should be prepared to discuss with CRO, among others: the purpose of the transmission; the identity of the transferee and the transferee; the nature of the data to be transmitted (data of human subjects? do they contain identifiers?); whether the data was collected as part of a research study or standard of treatment and, if there is a research study, whether restrictions may be imposed by third parties; whether an applicable declaration of consent allows the use or transmission of the proposed data; the way in which the data is transmitted; whether the patents are data-bound; and whether samples are sent with or in connection with the data. The Proponent has agreed to offer all funds referred to in this Agreement on the dates indicated. The DTAs that researchers receive from external parties for detailed records must be verified by a member of the research office`s contract team before the data is transferred, as the conditions must be carefully compared to the applicable funding conditions All other products and documents are the property of the institution and will remain so after the end and for the duration of the study. This Study Agreement may only be amended by mutual written consent of the authorized representatives of all Members who have currently entered into this Clinical Trials Agreement.
PandaTip: Sponsors of clinical trials often provide equipment or other assets, in addition to financial support. In this section of the model, you can describe in detail all the materials that the sponsor will provide during the clinical trial. PandaTip: This part of the agreement presentation for clinical trials serves as an area to protect both you and the sponsor from injuries affecting subjects in this clinical trial. The study begins with the approval of this contract and will be concluded either at the end of the contract or at the end of the study. This clinical trial agreement is mandatory and effective from [agreement.date]. The parties to this Agreement are referred to as the following, together referred to as “Parties”: all services provided by the Sponsor remain the property of the Sponsor during and after the completion of the Study. . . .